Literature DB >> 25870991

Impact of protease inhibitors on intracellular concentration of tenofovir-diphosphate among HIV-1 infected patients.

Cecile D Lahiri1, Sijia Tao, Yong Jiang, Anandi N Sheth, Edward P Acosta, Vincent C Marconi, Wendy S Armstrong, Raymond F Schinazi, Aswani Vunnava, Sara Sanford, Ighovwerha Ofotokun.   

Abstract

Intracellular nucleoside reverse transcriptase inhibitor (NRTI) concentrations are associated with plasma HIV-1 response. Coadministration of protease inhibitors with NRTIs can affect intracellular concentrations due to protease inhibitor inhibition of efflux transporters. Tenofovir-diphosphate (TFV-DP) concentrations within peripheral blood mononuclear cells were compared among individuals receiving either atazanavir or darunavir-based regimens. There was a trend towards higher TFV-DP concentrations among women and among participants receiving atazanavir. TFV-DP intracellular concentrations were positively associated with undetectable plasma HIV-1 RNA.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25870991      PMCID： PMC4490037          DOI： 10.1097/QAD.0000000000000659

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.177


  17 in total

1.  Evaluation of an upgraded version of the Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 test for HIV-1 load quantification.

Authors:  F Damond; V Avettand-Fenoel; G Collin; B Roquebert; J C Plantier; A Ganon; D Sizmann; R Babiel; J Glaubitz; M L Chaix; F Brun-Vezinet; D Descamps; C Rouzioux
Journal:  J Clin Microbiol       Date:  2010-02-03       Impact factor: 5.948

2.  Darunavir/ritonavir and efavirenz exert differential effects on MRP1 transporter expression and function in healthy volunteers.

Authors:  Lawrence S Lee; Gaik H Soon; Ping Shen; Eu-Leong Yong; Charles Flexner; Paul Pham
Journal:  Antivir Ther       Date:  2010

3.  Liquid chromatography-tandem mass spectrometric determination of tenofovir-diphosphate in human peripheral blood mononuclear cells.

Authors:  Tracy King; Lane Bushman; Jennifer Kiser; Peter L Anderson; Michelle Ray; Thomas Delahunty; Courtney V Fletcher
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2006-07-07       Impact factor: 3.205

Review 4.  HIV reservoirs and the possibility of a cure for HIV infection.

Authors:  S Palmer; L Josefsson; J M Coffin
Journal:  J Intern Med       Date:  2011-10-27       Impact factor: 8.989

5.  Zidovudine triphosphate and lamivudine triphosphate concentration-response relationships in HIV-infected persons.

Authors:  C V Fletcher; S P Kawle; T N Kakuda; P L Anderson; D Weller; L R Bushman; R C Brundage; R P Remmel
Journal:  AIDS       Date:  2000-09-29       Impact factor: 4.177

6.  Plasma and intracellular population pharmacokinetic analysis of tenofovir in HIV-1-infected patients.

Authors:  Gautam Baheti; Jennifer J Kiser; Peter L Havens; Courtney V Fletcher
Journal:  Antimicrob Agents Chemother       Date:  2011-09-06       Impact factor: 5.191

7.  Correlates of zidovudine phosphorylation with markers of HIV disease progression and drug toxicity.

Authors:  B N Stretcher; A J Pesce; P T Frame; K A Greenberg; D S Stein
Journal:  AIDS       Date:  1994-06       Impact factor: 4.177

8.  ATP binding cassette multidrug transporters limit the anti-HIV activity of zidovudine and indinavir in infected human macrophages.

Authors:  Sylvie Jorajuria; Nathalie Dereuddre-Bosquet; François Becher; Solenne Martin; Fabrice Porcheray; Alexia Garrigues; Aloise Mabondzo; Henri Benech; Jacques Grassi; Stéphane Orlowski; Dominique Dormont; Pascal Clayette
Journal:  Antivir Ther       Date:  2004-08

9.  Effect of protein binding on unbound atazanavir and darunavir cerebrospinal fluid concentrations.

Authors:  Cecile A Delille; Sarah T Pruett; Vincent C Marconi; Jeffrey L Lennox; Wendy S Armstrong; Richard F Arrendale; Anandi N Sheth; Kirk A Easley; Edward P Acosta; Aswani Vunnava; Ighovwerha Ofotokun
Journal:  J Clin Pharmacol       Date:  2014-04-08       Impact factor: 3.126

10.  Antiviral dynamics and sex differences of zidovudine and lamivudine triphosphate concentrations in HIV-infected individuals.

Authors:  Peter L Anderson; Thomas N Kakuda; Sagar Kawle; Courtney V Fletcher
Journal:  AIDS       Date:  2003-10-17       Impact factor: 4.177
View more
  11 in total

1.  Predictive Value of Tenofovir Diphosphate in Dried Blood Spots for Future Viremia in Persons Living With HIV.

Authors:  Mary Morrow; Samantha MaWhinney; Ryan P Coyle; Stacey S Coleman; Edward M Gardner; Jia-Hua Zheng; Lucas Ellison; Lane R Bushman; Jennifer J Kiser; Peter L Anderson; Jose R Castillo-Mancilla
Journal:  J Infect Dis       Date:  2019-07-19       Impact factor: 5.226

2.  Tenofovir Diphosphate in Dried Blood Spots Is Strongly Associated With Viral Suppression in Individuals With Human Immunodeficiency Virus Infections.

Authors:  Jose R Castillo-Mancilla; Mary Morrow; Ryan P Coyle; Stacey S Coleman; Edward M Gardner; Jia-Hua Zheng; Lucas Ellison; Lane R Bushman; Jennifer J Kiser; Samantha Mawhinney; Peter L Anderson
Journal:  Clin Infect Dis       Date:  2019-04-08       Impact factor: 9.079

3.  Intracellular Tenofovir and Emtricitabine Anabolites in Genital, Rectal, and Blood Compartments from First Dose to Steady State.

Authors:  Sharon M Seifert; Xinhui Chen; Amie L Meditz; Jose R Castillo-Mancilla; Edward M Gardner; Julie A Predhomme; Carolyn Clayton; Gregory Austin; Brent E Palmer; Jia-Hua Zheng; Brandon Klein; Becky J Kerr; L Anthony Guida; Caitlin Rower; Joseph E Rower; Jennifer J Kiser; Lane R Bushman; Samantha MaWhinney; Peter L Anderson
Journal:  AIDS Res Hum Retroviruses       Date:  2016-09-19       Impact factor: 2.205

4.  Intracellular Unbound Atorvastatin Concentrations in the Presence of Metabolism and Transport.

Authors:  Priyanka Kulkarni; Kenneth Korzekwa; Swati Nagar
Journal:  J Pharmacol Exp Ther       Date:  2016-07-22       Impact factor: 4.030

5.  Factors associated with tenofovir diphosphate concentrations in dried blood spots in persons living with HIV.

Authors:  Ryan P Coyle; Mary Morrow; Stacey S Coleman; Edward M Gardner; Jia-Hua Zheng; Lucas Ellison; Lane R Bushman; Jennifer J Kiser; Samantha MaWhinney; Peter L Anderson; Jose R Castillo-Mancilla
Journal:  J Antimicrob Chemother       Date:  2020-06-01       Impact factor: 5.790

6.  Intracellular Tenofovir and Emtricitabine Concentrations in Younger and Older Women with HIV Receiving Tenofovir Disoproxil Fumarate/Emtricitabine.

Authors:  Julie B Dumond; Camden P Bay; Julie A E Nelson; Angel Davalos; Andrew Edmonds; Kristina De Paris; Craig Sykes; Kathryn Anastos; Roopali Sharma; Seble Kassaye; Bani Tamraz; Audrey L French; Stephen Gange; Ighovwerha Ofotokun; Margaret A Fischl; David E Vance; Adaora A Adimora
Journal:  Antimicrob Agents Chemother       Date:  2020-08-20       Impact factor: 5.191

7.  Plasma and intracellular pharmacokinetics of tenofovir disoproxil fumarate and emtricitabine in transgender women receiving feminizing hormone therapy.

Authors:  Lauren R Cirrincione; Anthony T Podany; Joshua P Havens; Sara H Bares; Shetty Ravi Dyavar; Yeongjin Gwon; Tanner M Johnson; N Jean Amoura; Courtney V Fletcher; Kimberly K Scarsi
Journal:  J Antimicrob Chemother       Date:  2020-05-01       Impact factor: 5.790

8.  Tenofovir/emtricitabine metabolites and endogenous nucleotide exposures are associated with p16(INK4a) expression in subjects on combination therapy.

Authors:  Julie B Dumond; Owen Francis; Mackenzie Cottrell; Christine Trezza; Heather Ma Prince; Katie Mollan; Craig Sykes; Chad Torrice; Nicole White; Stephanie Malone; Ruili Wang; Cornelius Van Dam; Kristine B Patterson; Michael G Hudgens; Norman E Sharpless; Alan Forrest
Journal:  Antivir Ther       Date:  2016-01-05

9.  A Phase 1 Study to Evaluate the Drug Interaction Between Islatravir (MK-8591) and Doravirine in Adults Without HIV.

Authors:  Randolph P Matthews; Deanne Jackson Rudd; Kerry L Fillgrove; Saijuan Zhang; Charles Tomek; S Aubrey Stoch; Marian Iwamoto
Journal:  Clin Drug Investig       Date:  2021-06-21       Impact factor: 2.859

10.  Estimated Glomerular Filtration Rate Trajectories in HIV-Infected Subjects Treated With Different Ritonavir-Boosted Protease Inhibitors and Tenofovir Disoproxil Fumarate or Abacavir.

Authors:  Nicola Gianotti; Laura Galli; Andrea Poli; Stefania Salpietro; Silvia Nozza; Alessia Carbone; Marco Merli; Marco Ripa; Adriano Lazzarin; Antonella Castagna
Journal:  Medicine (Baltimore)       Date:  2016-05       Impact factor: 1.889
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.